NTC and STADA announce commercial partnership for portfolio of ophthalmic products in the MENA region

  • Sep 07, 2021

NTC, international pharmaceutical company headquartered in Milan, Italy, and STADA, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (MENA) region, today announce a commercial ophthalmic partnership.

NTC presents the Value report 2021 to its stakeholders

  • July 29, 2021

“Advanced scientific research and technology are the drivers of NTC’s innovation in care practices. While research is the soul of NTC, improving experience of care is our vocation which translates into new and specific therapeutic gestures: simple and intuitive, sustainable, and technically advanced for empowering the patient.” (Letter from the CEO)

Innovation in ophtha made in Italy: NTC has developed the first combination of levofloxacin and dexamethasone eye drops

  • May 13, 2021

NTC, an Italian pharmaceutical company specializing in ophthalmology, has developed the first eyedrops containing a fluoroquinolone wide spectrum antibiotic and a standard of care cortisone for the post-surgical treatment of cataract. The drug reduces the duration of therapy after surgery by 50%.

NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis

  • Jan 14, 2021

NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. READ MORE